Ardelyx, Inc. (ARDX) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low7.6·High7.6
P/B Ratio
↑
10.08
↑+71% vs avg
5yr avg: 5.89
30Y Low0.2·High8.4
ROE
↑
-36.2%
↓+46% vs avg
5yr avg: -67.0%
30Y Low-152%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARDX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ardelyx, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $1.4B | $1.2B | $1.4B | $452M | $115M | $145M | $121M | $25M | $78M | $142M |
| Enterprise Value | $1.9B | $1.5B | $1.3B | $1.4B | $393M | $88M | $110M | $-2608236 | $-4400586 | $3M | $68M |
| P/E Ratio → | -26.85 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.20 | 3.45 | 3.57 | 10.93 | 8.67 | 11.35 | 19.17 | 22.95 | 9.65 | 1.86 | 5.93 |
| P/B Ratio | 10.08 | 8.42 | 6.88 | 8.15 | 4.60 | 1.39 | 1.15 | 0.65 | 0.22 | 0.56 | 0.74 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ARDX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.80 | 3.84 | 11.20 | 7.53 | 8.69 | 14.47 | -0.49 | -1.69 | 0.07 | 2.82 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ARDX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Ardelyx, Inc. earns an operating margin of -10.1%. Operating margins have expanded from -50.8% to -10.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -36.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.5% | 89.5% | 84.8% | 85.7% | 92.1% | 90.1% | 98.1% | 88.6% | 82.1% | 80.0% | 94.6% |
| Operating Margin | -10.1% | -10.1% | -8.4% | -50.8% | -122.2% | -1528.6% | -1199.0% | -1728.1% | -3488.6% | -155.0% | -469.9% |
| Net Profit Margin | -15.1% | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% | -1245.7% | -1797.8% | -3502.0% | -153.2% | -467.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.2% | -36.2% | -23.0% | -49.8% | -74.3% | -151.6% | -60.3% | -62.8% | -71.6% | -38.7% | -74.4% |
| ROA | -13.1% | -13.1% | -10.7% | -27.1% | -39.5% | -90.0% | -40.9% | -42.9% | -53.5% | -34.7% | -68.1% |
| ROIC | -10.7% | -10.7% | -9.1% | -39.6% | -101.4% | -158.3% | -88.8% | -91.8% | -90.8% | -53.5% | -140.6% |
| ROCE | -10.6% | -10.6% | -9.2% | -34.1% | -57.6% | -114.2% | -44.2% | -45.3% | -59.5% | -39.0% | -74.5% |
ARDX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $144M ($212M total debt minus $68M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.27 | 1.27 | 0.89 | 0.34 | 0.37 | 0.55 | 0.44 | 0.31 | 0.42 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.86 | 0.51 | 0.21 | -0.61 | -0.33 | -0.28 | -0.66 | -0.26 | -0.54 | -0.39 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.44 | -1.44 | -0.93 | -6.38 | -12.25 | -34.13 | -17.50 | -15.53 | -24.83 | — | — |
ARDX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Ardelyx, Inc.'s current ratio of 4.31x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.88x to 4.31x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.31 | 4.31 | 4.58 | 4.88 | 2.34 | 2.53 | 6.87 | 11.36 | 10.02 | 8.39 | 10.62 |
| Quick Ratio | 4.11 | 4.11 | 4.31 | 4.64 | 2.29 | 2.53 | 6.87 | 11.36 | 10.02 | 8.39 | 10.62 |
| Cash Ratio | 2.99 | 2.99 | 3.21 | 3.66 | 1.89 | 2.21 | 6.56 | 11.14 | 9.48 | 7.50 | 10.46 |
| Asset Turnover | — | 0.81 | 0.77 | 0.42 | 0.27 | 0.07 | 0.04 | 0.02 | 0.01 | 0.27 | 0.11 |
| Inventory Turnover | 2.40 | 2.40 | 2.39 | 1.43 | 1.25 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 64.38 | 63.13 | 64.61 | 54.12 | 18.15 | — | 51.84 | 711.94 | 93.82 | — |
ARDX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ardelyx, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $241M | $235M | $219M | $159M | $104M | $90M | $64M | $56M | $47M | $40M |
Peer Comparison
Compare ARDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARDXYou | $2B | -26.8 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 CYCN | $14M | -2.9 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 CHRS | $213M | 1.2 | — | — | -37.3% | -429.5% | 275.4% | — | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 ASRT | $144M | -4.7 | 20.4 | — | 70.2% | -18.1% | -27.4% | -13.8% | 4.6 |
 VKTX | $4B | -9.9 | — | — | — | — | -47.3% | -44.4% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 AMGN | $178B | 23.1 | 14.1 | 21.9 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See ARDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARDX vs CYCN
Side-by-side business, growth, and profitability comparison vs Cyclerion Therapeutics, Inc..
Start ComparisonARDX — Frequently Asked Questions
Quick answers to the most common questions about buying ARDX stock.
What is Ardelyx, Inc.'s P/E ratio?
Ardelyx, Inc.'s current P/E ratio is -26.8x. This places it at the 50th percentile of its historical range.
What is Ardelyx, Inc.'s ROE?
Ardelyx, Inc.'s return on equity (ROE) is -36.2%. The historical average is -57.5%.
Is ARDX stock overvalued?
Based on historical data, Ardelyx, Inc. is trading at a P/E of -26.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Ardelyx, Inc.'s profit margins?
Ardelyx, Inc. has 89.5% gross margin and -10.1% operating margin.